PLANO, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, Diron Smith, Vice President and Interim Chief Financial Officer, and Andrew Senn, Senior Vice President, Strategy, Business Development & Investor Relations, are scheduled to participate at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023 at 1:30 p.m. ET.
A live webcast of the presentation will be available through Integer’s investor relations website at investor.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: | |
| Andrew Senn | Kelly Butler | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| 763.951.8312 | 214.618.4216 |
| Last Trade: | US$129.00 |
| Daily Change: | -0.68 -0.52 |
| Daily Volume: | 362,328 |
| Market Cap: | US$4.330B |
August 22, 2024 July 25, 2024 May 07, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
